The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.
Study design * Multicentre, randomized, single-blind, comparator-controlled, parallel-armed study * One year follow-up, or until relapse (whichever shorter) * 40-60 UK centres Subject population * Ulcerative colitis in remission (sigmoidoscopy score of 0 or 1 with no symptoms of active disease, with no treatment for active colitis) for at least 4 weeks, and for no more than 2 years * Taking mesalazine or sulfasalazine prior to study entry * Patients excluded if they have Crohn's disease, symptoms of active colitis, have used corticosteroids, ciclosporin or oral/enema mesalazine in the past 4 weeks, are intolerant to mesalazine or Asacol, are pregnant or lactating, or have known HIV, hepatic disease, renal impairment or other serious medical or psychiatric illness * Sample size 250 * Gender: male or female * Ethnicity: no restriction * Age: over 18 Test Product Once daily group: Asacol® 2.4g daily given as three 800mg tablets orally qAM Three times daily group: Asacol® 2.4g daily given as one 800mg tablet orally three times daily Criteria for Evaluation: Primary Outcome Variable: Relapse rate over 1 year in the intention to treat population, with the study powered to detect non-inferiority of the once-daily regimen. Secondary Outcome Variables: assessment of superiority of the once-daily regimen, if non-inferiority is demonstrated; safety analysis; per protocol analysis of relapse rate; time course of relapse; medication compliance; changes in modified Baron sigmoidoscopy scores between trial entry and relapse/12 month; impact of various factors on relapse rate (time from last relapse at study entry, concomitant azathioprine or 6-mercaptopurine therapy; disease extent; disease duration; smoking status; age at diagnosis; previous dose of mesalazine; baseline calprotectin; baseline CRP level).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
213
800 mg tablets
To assess whether a once daily dose of three 800mg tablets of mesalazine (Asacol®) in the morning is equivalent to mesalazine (Asacol®) given as 800mg three times daily in preventing relapse over a 12 month period.
Time frame: At relapse or 12 month follow up
To assess equivalence in terms of safety
Time frame: 12 months
To assess equivalence in terms of time to relapse
Time frame: 12 months
To assess equivalence in terms of progression of disease (measured by Mayo score)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Barnsley District General Hospital
Barnsley, United Kingdom
North Hampshire Hospital
Basingstoke, United Kingdom
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Selly Oak Hospital
Birmingham, United Kingdom
Bishop Auckland General Hospital
Bishop Auckland, United Kingdom
Blackpool Victoria Hospital
Blackpool, United Kingdom
Glan Clwyd Hospital
Bodelwyddan, United Kingdom
Pilgrim Hospital
Boston, United Kingdom
Princess Royal Hospital
Brighton, United Kingdom
Royal Sussex County Hospital
Brighton, United Kingdom
...and 35 more locations